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Abstract
Introduction The completion of an integrated PET/MR
prototype system for brain imaging is the latest step in the
evolution of positron emission tomography. Early images
with this new imaging system demonstrate that high-
resolution multiparametric studies can be combined without
significant loss of performance of either imaging modality.
Objective This new technology will make fusion of
morphological and biological information much easier,
yield real-time assessment of complementary variables
and will provide dynamic information for kinetic model-
ling. Simultaneous acquisition of various metabolic and
functional parameters may open new insights into the
organization of the brain and its changes in disease.
Discussion A new field may open up for molecular and
cellular imaging, where new targets – e.g. angiogenesis,
gene transfer, function and migration of transplanted cells –
can be imaged in the morphological context and within a
functional environment. This application might have a
special impact on the translation of treatment concepts
from experimental models into clinical application. If the
added value of the hybrid system for diagnosis and
treatment monitoring is established, a cost-effective PET/
MR combination might attain wider clinical application.
Keywords PET/MR . BrainPET. Image fusion .
High-resolution biological imaging .
Multi-parametric imaging . Gene transfer and expression .
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Introduction
Since the first prototypes [1, 2] and the first commercial
system [3], positron emission tomography (PET) has
developed to multiring systems permitting high resolution
and three-dimensional imaging of various physiological,
functional and molecular targets. The first applications of
PET were in brain research, and despite the many other
diagnostic indications, particularly in oncology and cardi-
ology, brain imaging remains a stronghold of PET.
Therefore, this discussion of perspectives of an integrat-
ed PET/MR system is focused on research applications in
neuroscience to which the combination of PET and MRI
may add further impetus. This perspective is in parts
speculative and it does not include a discussion of the
technical or methodological challenges of combined PET/
MR imaging. These aspects are reviewed elsewhere in the
articles of this supplement to EJNMMI.
Development of PET for brain imaging
The progress in image quality may be followed by metabolic
images of glucose consumption in one volunteer acquired on
several generation PET systems over the years. The first
transaxial image (Fig. 1a) was acquired on a single hexagonal
array, the ECAT PET, which covered only the cortical rim.
Early PET images suffered from limited spatial resolution
(approximately 15 mm), low sensitivity and insufficient
attenuation and scatter correction [3, 4]. PET image quality
improved with the four-ring PC-384 (Scanditronix) [5],
which yielded seven simultaneous, partly overlapping trans-
axial images and that provided a spatial resolution of 8.4 mm
FWHM across 12-mm slices (Fig. 1b) [6] and limited axial
reconstruction (Fig. 2). Further improvements came with the
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ECAT EXACT PET, which yielded 47 contiguous image
planes with a spatial resolution of 6.5–7 mm and 5–8 mm in
the transverse and axial directions, respectively (Fig. 2) [7].
For the first time the entire brain could be imaged in a single
PET examination. The next generation PET system, the
ECAT EXACT HR, provided further improvements of the
spatial resolution (3.6 mm and 4.0 mm in the transverse and
axial direction, respectively), sensitivity and image quality
[8] (Figs. 1 and 2). With the dedicated high-resolution
research tomograph (HRRT) PET image resolution improved
to 2.3 mm and 2.5 mm in the transaxial and axial directions,
respectively, while sensitivity has increased to 4.3% [9, 10]
(Figs. 1 and 2).
The most attractive feature of PET is the high sensitivity
and specificity in detecting biochemical and molecular
tracers, but it suffers from limited spatial resolution.
Therefore, coregistration of PET images with morpholog-
ical imaging modalities such as CT and MRI has been
studied [11, 12], but is not yet in routine clinical use.
Research applications of image fusion software have also
been challenged by, for example, mapping of molecular and
genetic activities to certain cortical areas.
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Fig. 1 Various PET systems
over the years demonstrate im-
provement in image quality and
spatial resolution. a ECAT II,
spatial resolution 15 mm. b PC-
384, FWHM 8.4 mm. c ECAT
EXACT, FWHM 6.5–7 mm. d
ECAT EXACT HR, FWHM
3.6–4.5 mm. e, f HRRT PET: e
prototype; f final version (HRRT-
FV), FWHM 2.3–3.2 mm.
Images of glucose metabolism
were acquired for 20 min of
steady-state starting 30 min after
tracer administration
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Fig. 2 Coronal views of
glucose consumption of
the brain in a volunteer acquired
with various PET systems over
the years demonstrate improve-
ment in axial resolution due to
decreased slice thickness and
advances in image reconstruc-
tion. a ECAT II (1980) was a
single-ring camera; axial recon-
struction was therefore not fea-
sible. b PC-384, slice thickness
12 mm. c ECAT EXACT, axial
FWHM 5–8 mm. d ECAT EX-
ACT HR, axial FWHM
4.0–6.7 mm. e, f HRRT PET: e
prototype; f final version
(HRRT-FV), axial FWHM
2.5–3.4 mm
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The integration of PET and CT into one imaging system
permitting a simple overlay of sequentially acquired images
has been a great success in clinical diagnosis [13].
However, because of the limited soft-tissue specificity of
CT, this integrated system is not of great value for brain
imaging. The installation of a HRRT PET system adjacent
to a high-field 7T MRI system allows the utilization of high
sensitivity molecular/biochemical and high-resolution ana-
tomical imaging for brain research [14]. However, this
system is not integrated and therefore does not permit
simultaneous PET and MR data acquisition. For that
purpose an integrated PET/MR system is required, which
would permit the simultaneous coregistration of various
MR and PET procedures. Schmand et al. demonstrated for
the first time that simultaneous PET and MR data
acquisition is feasible with an integrated PET/MR tomo-
graph [15]. Figure 3 shows the first simultaneously
acquired MR and PET images [16] in a volunteer and
demonstrates the feasibility of combined MR and PET data
acquisition without significant interference between the two
modalities. Conventional MR imaging on a 3-T MR
tomograph was performed using a T2-weighted turbo-spin
echo sequence, a fluid attenuated inversion recovery
sequence and a 3-D T1-weighted fast low-angle shot
sequence. Additionally, diffusion-weighted imaging, time-
of-flight MR angiography (MRA) and proton MR spec-
troscopy were performed during the acquisition of the PET
data. For PET imaging 370 MBq of 18F-fluorodeoxy-D-
glucose was intravenously injected and the activity in the
head was accumulated over 40 min, starting 20 min after
tracer injection. PET images were reconstructed using a 3D-
OSEM algorithm following scatter, randoms and attenua-
tion correction. The resolution of the reconstructed images
was 2.5 mm FWHM at the centre and 4.5 mm at 10 cm off-
axis with a sensitivity of 5.6%. Overall, the quality of the
images was comparable to that of the corresponding stand-
alone PET and MRI systems [16].
Advantages of an integrated PET/MR system for image
fusion
With the installation of PET/MR systems in a clinical




Fig. 3 PET/MR imaging with
BrainPET system in a volun-
teer. Three representative or-
thogonal slices demonstrate the
alignment of anatomic (3-D T1-
weighted MRI) and metabolic
images (FDG-PET). Asymme-
tries in the frontotemporal cor-
tex are related to small white
matter hyperintensities
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already utilized in preclinical research already is on the
verge of being applied to the clinical neurosciences [17,
18]. An integrated PET/MRI system will permit the
simultaneous acquisition of several parameters (Table 1).
Quantitative values from PET (some in the picomolar
range) of a large number of biological parameters are
complemented by the high-resolution information provid-
ed by MRI (in the micromolar range) to yield comple-
mentary information of previously unexpected variability.
The combination of imaging modalities for high sensi-
tivity and high resolution with the additional advantage of
utilizing dynamic acquisition procedures appears very
appealing for a variety of clinical and research applications.
Recently, PET data and MRI data have been retrospectively
combined for detection and staging of gliomas [19, 20] as
well as for identification of areas with critical neurofunction
in the vicinity of tumours, which is important for planning
surgery [21]. Image fusion has gained a place in the early
diagnosis of dementia and mild cognitive impairment [22]
and degenerative disorders, e.g. cerebral atrophy and
Huntington chorea. Image fusion is of clinical value in the
detection of epileptic foci accessible for surgery [23] and
for the identification of metabolic activity, transmitter
concentration and enzyme expression in small brain
structures [24]. In experimental focal brain ischaemia and
ischaemic stroke, coregistration of regional values for
cerebral blood flow, oxygen utilization and glucose metab-
olism on early and late MRI has permitted the differenti-
ation of irreversibly damaged areas and functionally
impaired but morphologically preserved areas, thus affect-
ing treatment strategies [25].
Real-time imaging of complementary information
The established applications of coregistered MRI and PET
will gain new dimensions with the simultaneous procedures
made possible by integrated PET/MR. Simultaneous data
acquisition will allow the addition of kinetic, functional and
metabolic information for real-time multiparametric imag-
ing. The vascular origin of changes in cerebral blood flow,
oxygen consumption and metabolism causing stroke
and intracerebral and subarachnoid haemorrhages can be
detected byMRA. Perfusion changes can be related directly
to the extent of hypoxia (18F-MISO-PET) and changes in
metabolic markers (e.g. lactate, choline and N-acetyl-
aspartate) can be assessed through simultaneous PW-MRI,
MRS and 18F-MISO-PET. Diffusion- and perfusion-weighted
(DW-PW) MRI can be performed during PET measurements
of 15O and H2
15O for differentiation of intervascular
perfusion, tissue blood flow, penumbra and irreversible tissue
damage in ischaemic stroke [26]. This differentiation is
important for therapeutic decision. For that purpose the
validation of MR surrogate measures (mismatch between
PW- and DW-MRI) is needed. The combination of various
MRS procedures with PET will broaden the insight into the
complex metabolic changes caused by brain diseases.
Coregistration of image data from the different
modalities has indicated the value of such comparative
studies in stroke [27], gliomas [28], and degenerative [29]
and congenital or hereditary disorders [30]. However,
coregistration was limited since it required multiple inves-
tigations in different laboratories. Real-time simultaneous
studies will be of particular interest for the interpretation of
activation patterns (intravascular versus tissue signals)
obtained with fMRI and H2
15O (or FDG) PET [31, 32]
and will be useful for the analysis of the effect of specific
tasks on transmitter release and receptor binding, such as
the determination of DOPA, raclopride and 5-hydroxy-
tryptamine transporter by combining fMRI with PET [33–
35]. A similar approach (fMRI and PET of receptor ligands)
might be useful to elucidate the effects of drugs and their
withdrawal (e.g. nicotine) on task performance. However,
in these combined applications of fMRI and PET the
differences in temporal resolution and sampling must be
considered: separated short time frame MRI (~ seconds)
versus PET acquisitions of several minutes.
Dynamic data for modelling
The high temporal resolution of MRI can be utilized for the
acquisition of dynamic data can be utilized for the quantifi-
cation of metabolic values by PET. For example, flow-
dependent kinetic constants can be determined by PWI and
used for compartmental analysis of PET data (e.g. FDG, FLT)




Water motion in tissue (DWI) Metabolism (FDG)
Vascular anatomy (MRA) Blood volume (C15O)
Perfusion (PWI, DCE-MRI) Oxygen consumption (15O)
Tissue metabolites
(MRS for 1H, 13C, 23Na, 31P)
Vascular permeability
(labelled AA)
Functional activation (fMRI) Nucleic acid synthesis (FLT)
Cerebral fibre tracts (DTI) Transmitters (e.g. DOPA)
Oxygen consumption (17O) Receptors (e.g. raclopride)
Migration of cells (Fe labelling) Enzymatic activity (e.g. MP4A)
Angiogenesis (e.g. 18F-RGB)
Distribution and kinetics of
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[36] or for the assessment of the kinetics of the distribution
of tracers or labelled drugs in various brain structures [37].
Simultaneous data acquisition by MRI and PET could
also be used to develop new methods, e.g. values of
cerebral blood flow obtained by arterial spin labelling MRI
can be validated by H2
15O-PET [38], and 17O as a new
MRI tracer for oxygen utilization [39] can be compared to
cerebral metabolic rate of O2 as determined by PET. This
promising new MRI method uses inhalation of air enriched
with 17O2 whereby the inhaled
17O is converted into H2
17O
in proportion to the oxygen consumption. The metabolite
H2
17O perturbs the proton signal resulting in negative
contrast on T2-weighted MRI. Thus, the signal intensity is
proportional to oxygen consumption.
124 I]-FIAU-PET after targeted therapy
68 h p.i.
1 h p.i.





Fig. 5 Coregistration of FIAU-PET, MET-PET, FDG-PET and MRI for evaluation after targeted therapy in the active tumour centres, the effect of




Fig. 4 Coregistration of MRI with diffusion tensor tracking and PET
15O water activation studies demonstrates the effect of stimulation of
the nucleus accumbens by flow increase in the striatum and various
cortical regions. Diffusion tractography depicts the anatomical path-
ways between the stimulated region and the activated subcortical and
cortical areas
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Multiparametric functional imaging
For complex studies of brain function special combinations of
modalities or additional investigative procedures may open
new insights into the organization of the brain and diseases–
related changes of brain function. For these studies diffusion
tensor tracking will add new dimensions, since it could be
performed in close temporal relation to activation studies
mapping the effects on transmitter release and receptor
occupancy as well as on metabolism in connected areas of
functional networks [40]. With this approach the effect of
deep brain stimulation, which is a means to ameliorate
neurological symptoms and to improve abnormal behaviour
[41] could be demonstrated. The effect of such an invasive
manipulation on metabolism in defined regions together with
the connecting fibre tracts is shown in Fig. 4. It may also be
possible to analyse the effect of repetitive transcranial
magnetic stimulation (rTMS), which can be used to activate
or inhibit selected areas of the cortex, on regional metabo-
lism, and on the involvement of transmitter/receptor systems
and the connecting network [42].
Perspectives for molecular and cellular imaging
Fusion of PET and MR images has been used in several
attempts to identify molecular events induced by local
pathogenetic factors, by the transfer of genetic material or
implantation of (stem) cells. While the above studies were
performed using separate imaging modalities, it is possible
that these concepts could be transferred more easily to
routine applications in humans through an integrated PET/
MR tomograph, by which various functional and morpho-
logical aspects can be observed simultaneously. In several
of these applications the identification of small regions or
cell clusters by MRI might be essential for the analysis of
biochemical processes by PET. Therefore, these examples
may create new combined applications of MR and PET.
Angiogenesis is a fundamental process in various
physiological and pathological processes. Visualization,
quantification and monitoring of angiogenesis is of interest
in various fields, including oncology and cardiology.
Molecules regulating angiogenesis include growth factor
receptors and integrins. Cyclic RGD peptides bind to
integrin ανβ3, and
18F-galacto-RGD has been tested in
humans with high uptake in highly vascularized tumours.
Alternatively, labelled ligands have been used to study the
vascular endothelial growth factor receptor. When combined
with dynamic, contrast-enhanced MR, yielding vascular and
extravascular volumes, vascular permeability and perfusion
angiogenesis PET markers may permit the follow-up of
angiogenetic and antiangiogenetic treatment [43].
Targeted gene transfer by various vectors can be used to
express foreign enzymes in cells. This strategy can be
6 days 8 days
GFP+ / NeuN+ GFP+ / GFAP+
a b
dc
Fig. 6 Images of stem cell
migration toward the stroke ter-
ritory by 3-D T2*-weighted
MRI (a, b) and assessment of
functional activity of implanted
cells after migration to the
stroke border zone (c, d). Yellow
arrows indicate the implantation
site (a), red arrows indicate
migrating stem cells (a, b).
Immunohistochemistry indicates
differentiation of stem cells
(green fluorescent protein) into
neurons (neuronal specific nu-
clear protein) (c) and glial cells
(glial fibrillary acidic protein)
(d). From Hoehn et al. [47]
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applied to make malignant cells susceptible to specific
drugs, which are toxic only to those cells expressing the
enzymes. In an experimental glioma model the efficacy of
this treatment strategy with transfer of the herpes virus
thymidine kinase gene and application of ganciclovir has
been demonstrated and preliminary clinical tests have
shown some efficacy of this treatment [44]. The effect of
this therapy can be followed by multitracer PET and
verified on MRI (Fig. 5).
Implantation of embryonic stem cells into the striatum
lesioned by injection of 6-OHDA in rats leads to prolifer-
ation and differentiation of dopaminergic cells. This was
demonstrated by coregistering MRI and PET of the specific
dopamine transporter ligands 11C-CFT [11C-2β-carbome-
thoxy-3β-(4-fluorophenyl) tropane] where CFT binding
was restored in the region of TH-immunoreactive neurons
documented post mortem. The restored functional activity
of these implanted cells was demonstrated by the response
to amphetamine, which caused an increase in rCBV due to
dopamine release [45]. Simultaneous PET/MR can be used
to show the viability and differentiation of transplanted
cells and their effect on neuronal networks [46]
Cell replacement approaches are an innovative strategy
for treatment of various neurological disorders. For the
development of these approaches in animal models it is
essential to monitor the location and to follow the migration
of grafted stem or progenitor cells. Various strategies have
been proposed for labelling these cells with ultrasmall
superparamagnetic iron oxide particles and micron-sized
iron oxide particles [47]. In focal experimental ischaemia
labelled stem cells migrated over 3 weeks from the
contralateral implantation site along the corpus callosum
to the ventricular walls and massively populated the border
zone of the damaged brain tissue on the lesioned hemi-
sphere (Fig. 6). A combination of MRI for tracking cells
and of PET for proving their biological activity could
demonstrate the viability of the cells as well as their
integration into functional networks [48]. Monitoring cell
viability and migration by MRI combined with indicators of
function from PET might also become a qualifying step in
strategies relying on transplantation of fetal grafts, e.g. in
Parkinson disease.
Conclusion
Integrated PET/MR holds great potential for brain research,
especially for multiparametric analysis of complex function
in neuronal networks, for the imaging of complex molec-
ular processes of gene transfer and cell transplantation and
for the translation of new treatment strategies from
preclinical research into clinical application. If the superi-
ority of integrated PET/MR in diagnostic accuracy and
treatment monitoring can be proven and if the integration of
the two modalities is cost effective it may also become an
instrument for routine clinical use.
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